Experimental ALS Drug Shows Unprecedented Recovery in some Patients

Experimental ALS drug shows unprecedented recovery in some patients

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he's unwaveringly honest.

This experimental drug could help young people with a rare and aggressive form of ALS

Researchers say a full-scale clinical trial of the therapy could help many patients with a particularly aggressive form of ALS

Experimental drug may benefit some patients with rare form of ALS

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he's unwaveringly honest. "Patients always ask me, 'What can I hope to get out of this?"' Shneider says. "And I always say, in most clinical trials, our hope is that we can slow the disease or maybe even halt progression."

A young woman who could not walk or breathe alone due to a rare genetic form of amyotropic lateral sclerosis (ELA-FUS) has regained her functions after receiving an experimental treatment called ulefnersen. Researchers at the Irving Medical Center at Columbia University (United States) have presented data on 12 patients, all treated with a new therapy for a rare form of amyotropic lateral sclerosis (ELA) caused by a genetic mutation in a gene ca…

The model of integrated care in the ELA of the management of Alcázar de San Juan (Ciudad Real), protagonist in the regional days held in Cuenca

Experimental drug 'Ulefnersen' offers unprecedented hope for rare form of ALS

An experimental drug known as ulefnersen has shown remarkable efficacy in treating a rare, aggressive form of ALS. Some patients experienced unprecedented functional recovery, offering new hope in a previously devastating diagnosis In a surprising and deeply motivating turn for the ALS research community and patients, an experimental drug has shown remarkable efficacy in treating a rare, aggressive form of Amyotrophic Lateral Sclerosis (ALS) cau…